Clinical Trials | A multinational, open-label study to investigate efficacy and safety of denecimig (Mim8) in adults with acquired haemophilia A
A multinational, open-label study to investigate efficacy and safety of denecimig (Mim8) in adults with acquired haemophilia A
The University of Virginia is conducting a clinical research study for adults ages 18 and over for patients who have newly diagnosed acquired hemophilia A. The purpose of this study is to find out if denecimig is safe and effective for treating people who have acquired hemophilia A. If you decide to take part in this study, you will be in this clinical study for up to around 1 year and 5 months. You will take the study medicine for up to 1 year. After you finish your study treatment, your doctor will continue to follow your condition for up to 5 months to check on your health after the treatment has stopped. Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance. Additional information can be found here: https://clinicaltrials.gov/study/NCT07830732 [email protected]